FOXM1 is co-expressed with its bidirectional gene partner RHNO1, and the two genes promote DNA repair, cell growth and survival, and chemotherapy resistance in ovarian cancer.
Application of machine learning to serum miRNA profiles generated through next generation sequencing identifies a biologically relevant miRNA signature which can be deployed as a qPCR test to assist the diagnosis of epithelial ovarian cancer.
PARP-7 is a mono(ADP-ribosyl) transferase that directs an extensive ADP-ribosylated proteome to control microtubule stability, and regulate ovarian cancer cell growth and motility.
Genomic gains in ovarian cancer can promote cisplatin resistance via a FAK, Wnt/beta-catenin and Myc signaling pathway supporting pluripotency genes and tumorspheres that can acquire FAK dependence for survival.
A functional ovarian-specific PAX8-centric regulon is susceptible to FDA-approved HDAC inhibitors, providing the rationale to target human cancers driven by lineage-survival oncogenes with epigenetic therapeutics perturbing the enhancer topology.
Endothelial cells express a soluble isoform of the L1CAM cell adhesion molecule that is generated by the splicing factor NOVA2 and induces angiogenesis, with relevant implications for ovarian cancer vascularization.
Inhibition of ITGA2-mediated cancer cell-collagen interaction or targeting focal adhesion kinase activity may present an opportunity for therapeutic intervention of metastatic spread in ovarian cancer.
A multi-transcriptional CDKs inhibitor suppresses MYC and induces regression of ovarian tumors, indicating that targeting CDK7, 12, 13 with THZ1 may be an effective approach for treating MYC-dependent malignancies.
A genome-wide in vivo CRISPR screen identifies an IL-20/IL20RA-mediated crosstalk between peritoneum mesothelial cells and ovarian cancer cells that promotes the formation of M1-like macrophages to prevent ovarian cancer metastasis.
